ASCO 2015: Pembrolizumab Shows Promising Activity Against Head and Neck Cancer

A 132-patient study indicates that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC). The findings may fill a large unmet need for better tr... Author: EMJ Added: 05/31/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts